Assessing Appropriate Utilization of SGLT2 Inhibitors in Type II Diabetic Patients

Abstract

Specific Aims: To determine if SGLT2 inhibitors were used appropriately in type II diabetic patients at El Rio Health Center given their estimated glomerular filtration rate (eGFR). Subjects: El Rio Health Patients with a formal diagnosis of type II diabetes prescribed an SGLT2 inhibitor. Methods: In this retrospective analysis, informatic specialists provided a de-identified report of type II diabetic patients on SGLT2 inhibitors with renal function labs available. The data was retrieved from July 2019-July 2020. Evaluation of appropriate use of SGLT2 inhibitors was assessed by comparing the patient’s eGFR to current dosing guidelines for each individual SGLT2 inhibitor. Main Results: Of the 234 patients evaluated, the average age of the subjects was 69 years old with 54% being of Caucasian descent. An average eGFR of 85 mL/min./1.73m^2 in patients with included comorbidities of 94% hyperlipidemia, 87% hypertension, and 15% cardiovascular disease. In the observed population, nearly 95% of patients were appropriately prescribed SGLT2 inhibitors based on current eGFR and current dosing guidelines. Conclusions: Based on the analyzed data, a majority of type II diabetic patients at El Rio Health Center were appropriately prescribed an SGLT2 inhibitor for their eGFR based on current guideline recommendations.